Iscar for Supplemental Care in Stage IV Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00079794 |
Recruitment Status
:
Completed
First Posted
: March 16, 2004
Last Update Posted
: January 25, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Cancer | Drug: Iscar Drug: mistletoe | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 36 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Iscar for Supplemental Care in Stage IV Lung Cancer |
Study Start Date : | September 2001 |
Actual Primary Completion Date : | February 2004 |
Actual Study Completion Date : | February 2004 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Stage IV NSCLC patients who receive standard chemotherapy
Exclusion criteria:
- Known allergy to Viscum Album L.
- Concomitant use of other mistletoe products
- Concomitant use of mushroom glucan and proteoglycan extracts
- Concomitant use of thymus extract products
- Inability to self-report quality of life utilizing assessment tools
- Ongoing steroid or ACTH therapy
- Co-morbid immunocompromised state
- Pregnancy
- Participation in other clinical trials

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00079794
United States, Pennsylvania | |
Thomas Jefferson University | |
Philadelphia, Pennsylvania, United States, 19107 |
Principal Investigator: | Steven Rosenzweig, MD | Jefferson Medical College of Thomas Jefferson University |
ClinicalTrials.gov Identifier: | NCT00079794 History of Changes |
Other Study ID Numbers: |
R21AT001020-01 ( U.S. NIH Grant/Contract ) Rosenzweig |
First Posted: | March 16, 2004 Key Record Dates |
Last Update Posted: | January 25, 2008 |
Last Verified: | January 2008 |
Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
lung cancer herbal medicine non-small cell cancer Iscar mistletoe |
Additional relevant MeSH terms:
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |